Solomon Hamburg is an Oncology physician affiliated with University of California, Los Angeles. OpenAlex indexes 28 publications with 1,383 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
15503 Ventura Blvd Ste 150
Encino, CA 914363115
Telephone
818-995-8044Registry record last updated 19 Aug 2019.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year202514 payments$17,859openpaymentsdata.cms.gov ↗
- PharmaEssentia USA CorporationProgram year20254 payments
- BeOne Medicines USA, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
59.5%Erythropoiesis-stimulating Agent59.4%Darbepoetin alfa100%Part B, office-administered≥22 patientsFactor Xa inhibitor0.1%Eliquis61%Xarelto39%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
20.4%Other antiemetics16.3%Fosaprepitant100%Part B, office-administered≥16 patientsSerotonin-3 Receptor Antagonist4%Ondansetron hydrochloride77%Palonosetron hcl23%Part B, office-administered≥29 patients+ 1 more class in this area
Musculoskeletal
15.6%RANK Ligand Inhibitor15.5%Denosumab100%Part B, office-administered≥25 patientsXanthine oxidase inhibitor0%Allopurinol100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1997–2001 per NIH RePORTER. The latest:
- WOMEN'S INTERVENTION NUTRITION STUDY
la Biomed Res Inst/ Harbor Ucla Med Ctr
FY2001$237,978M01RR000425
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Complex Tricuspid and Pulmonic Carcinoid Heart Disease With Timely Surgical Repair
Texas Heart Institute Journal
2025 - Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 – 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study
Clinical Lymphoma Myeloma & Leukemia
2021 - Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
Journal of Hematology & Oncology
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Gregg Fonarow, MD
University of California, Los Angeles
Dennis Slamon, MD
University of California, Los Angeles
Tomas Ganz, MD
University of California, Los Angeles
Richard Casaburi, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”